Viva Biotech Holdings (HKSE:01873) Long-Term Debt : HK$1,008 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Long-Term Debt?

Viva Biotech Holdings's Long-Term Debt for the quarter that ended in Dec. 2023 was HK$1,008 Mil.

Viva Biotech Holdings's quarterly Long-Term Debt declined from Dec. 2022 (HK$984 Mil) to Jun. 2023 (HK$644 Mil) but then increased from Jun. 2023 (HK$644 Mil) to Dec. 2023 (HK$1,008 Mil).

Viva Biotech Holdings's annual Long-Term Debt declined from Dec. 2021 (HK$2,924 Mil) to Dec. 2022 (HK$984 Mil) but then increased from Dec. 2022 (HK$984 Mil) to Dec. 2023 (HK$1,008 Mil).

Viva Biotech Holdings Long-Term Debt Historical Data

The historical data trend for Viva Biotech Holdings's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Long-Term Debt Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

1.49

3,317.59

2,924.25

983.78

1,008.48

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Long-Term Debt	Get a 7-Day Free Trial										2,748.84	983.78	644.30	1,008.48	-

Viva Biotech Holdings (HKSE:01873) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Viva Biotech Holdings Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

VBIZF:USA VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation (CDMO) and commercialisation services segment include contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates, and formulations. Geographically, the company generates a majority of its revenue from the United States of America, and the rest from the European Union, Chinese Mainland, Africa, and other regions.

Executives

Mao Chen Cheney	2101 Beneficial owner
Wu John Jiong	2201 Interest of corporation controlled by you
Fenghe Harvest Ltd	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Mao Jun	2501 Other
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Zhou Min	2202 Interest of your spouse
Intertrust (singapore) Ltd.	2301 Trustee
Z&m International Holdings Limited	2201 Interest of corporation controlled by you
Zhang And Sons Limited	2101 Beneficial owner

Viva Biotech Holdings Headlines

No Headlines